Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
Fierce Pharma

Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue

Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a ...

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company’s Audit ...

Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker

Acadia Pharmaceuticals' two approved drugs, NUPLAZID and DAYBUE are guided to continue their strong growth trajectories. Read ...

Acadia Healthcare Stock Has Tanked This Past Year, and One Fund Just Called It Quits on a $13 Million Stake

Acadia Healthcare runs a major U.S. behavioral health network, providing inpatient and outpatient care for mental health and addiction.

European Regulators Recommend Against Acadia's Application for Rett Syndrome Treatment

A European regulatory body adopted a negative opinion regarding Acadia Pharmaceuticals' application for trofinetide, its treatment for Rett syndrome, a rare neurodevelopmental disorder seen in ...
The Ellsworth American

Three Acadia trails closed for nesting season

To provide peregrine falcons adequate space for nesting, the National Park Service has temporarily closed areas including ...

Why the 2026 GMC Acadia is a standout family SUV

The 2026 GMC Acadia midsize SUV impressed with its powerful engine, spacious interior and comfortable ride. See if this ...